

B₁
Cont

- b) obtaining recipient cells from the patient;
- c) contacting the donor cells with an immunoglobulin specific to B7-1, an immunoglobulin specific to B7-2, and recipient cells from the patient such that the donor cells, the recipient cells, the immunoglobulin specific to B7-1, and the immunoglobulin specific to B7-2 are in contact for a period of time from about 1 to about 48 hours, thereby obtaining a mixture, and
- d) introducing the mixture after the contacting step of c) to the patient.

B₂

9. (Twice Amended) A method for transplanting cells to a patient in need thereof, comprising:
- a) obtaining cells from a donor,
 - b) obtaining a tissue, an organ, or recipient cells from the patient,
 - c) contacting the donor cells with an immunoglobulin specific to B7-1, an immunoglobulin specific to B7-2, and the tissue, the organ, or the recipient cells that express MHC Class I antigen, B7-1 and B7-2 molecules, such that the donor cells, the tissue organ or recipient cells, the immunoglobulin specific to B7-1, and the immunoglobulin specific to B7-2 are in contact for a period of time from about 1 to about 48 hours, thereby obtaining a mixture, and
 - d) introducing the mixture after the contacting step of c) to the patient.

Please add new claim 11 as follows:

11. (New) The method of claim 1, wherein the immunoglobulin specific to B7-1 and the immunoglobulin specific to B7-2 are humanized.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

B₃

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com